EIC Accelerator

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Iktos is a French company specializing in artificial intelligence-driven solutions for medicinal chemistry and new drug discovery. It offers SaaS platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, accelerating pharmaceutical R&D. Iktos also develops AI-driven synthesis automation platform Iktos Robotics and has its own drug pipeline targeting oncology and autoimmune diseases.

NanoPhoria is a biotechnology company focused on cardiovascular therapies. It develops non-viral, nanoparticle-based drug delivery platforms designed to target the heart directly and improve the delivery of biologics, including peptides and RNAs. The company is pursuing tissue-directed delivery methods and inhalable formulations, with preclinical programs aimed at treating cardiovascular diseases such as heart failure with reduced ejection fraction. Its platform enables selective organ- and cell-level targeting to expand administration routes beyond traditional systemic delivery, supporting research and development to advance cardiovascular health.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

StarTric develops a minimally invasive device for treating tricuspid regurgitation, a common cause of heart failure. Their transcatheter repair implant reduces blood flow to the lungs, preventing symptoms such as atrial fibrillation and improving patient outcomes.

StarTric develops a minimally invasive device for treating tricuspid regurgitation, a common cause of heart failure. Their transcatheter repair implant reduces blood flow to the lungs, preventing symptoms such as atrial fibrillation and improving patient outcomes.

MyoPax develops advanced regenerative therapies using stem cells to address debilitating muscle illnesses.

Neurescue ApS, headquartered in Copenhagen, Denmark, specializes in developing innovative medical devices aimed at addressing cardiac arrest and hemorrhage. Established in 2014, the company has introduced its flagship product, the safeREBOA device, which is recognized as the first computer-aided aortic occlusion catheter designed to enhance the care of emergency patients. Neurescue's commitment lies in improving resuscitation rates and extending critical treatment time through advanced cardiovascular solutions. The organization is focused on advancing the clinical utility of its devices to ultimately save lives in emergency situations.

NanoPhoria is a biotechnology company focused on cardiovascular therapies. It develops non-viral, nanoparticle-based drug delivery platforms designed to target the heart directly and improve the delivery of biologics, including peptides and RNAs. The company is pursuing tissue-directed delivery methods and inhalable formulations, with preclinical programs aimed at treating cardiovascular diseases such as heart failure with reduced ejection fraction. Its platform enables selective organ- and cell-level targeting to expand administration routes beyond traditional systemic delivery, supporting research and development to advance cardiovascular health.

Captor Therapeutics is a bio-pharmaceutical firm focused on development of protein degradation drugs for cancer and autoimmune diseases. Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called "undruggable proteome".

Invitris is a biotech company focused on developing protein-based drugs and manufacturing bacteriophages to combat antibiotic-resistant bacteria. The company specializes in synthesizing arbitrary phages within a single system, which allows for effective quality assessment, synthetic phage production, and quality control services. By enabling personalized diagnostics, Invitris aims to provide patients with targeted treatments for bacterial infections, ensuring both safety and practical application in the fight against resistant pathogens.

MyoPax develops advanced regenerative therapies using stem cells to address debilitating muscle illnesses.

Invitris is a biotech company focused on developing protein-based drugs and manufacturing bacteriophages to combat antibiotic-resistant bacteria. The company specializes in synthesizing arbitrary phages within a single system, which allows for effective quality assessment, synthetic phage production, and quality control services. By enabling personalized diagnostics, Invitris aims to provide patients with targeted treatments for bacterial infections, ensuring both safety and practical application in the fight against resistant pathogens.

TetraKit Technologies is a Copenhagen-based company founded in 2021 that specializes in a click chemistry-based radiochemical platform aimed at developing therapeutics for metastatic cancer. The company offers a targeted radionuclide therapy and nuclear imaging platform for cancer diagnosis, utilizing radiopharmaceuticals such as fluorine-18 and astatine-211 for positron emission tomography (PET) imaging and targeted alpha-radionuclide therapy. TetraKit's innovative approach incorporates proprietary click chemistry and a modular design, which allows for rapid and mild labeling conditions across a variety of molecules. This platform enhances the efficiency of production processes in the field of radiopharmaceuticals, enabling medical professionals to leverage advanced technologies in cancer treatment and imaging.

TetraKit Technologies is a Copenhagen-based company founded in 2021 that specializes in a click chemistry-based radiochemical platform aimed at developing therapeutics for metastatic cancer. The company offers a targeted radionuclide therapy and nuclear imaging platform for cancer diagnosis, utilizing radiopharmaceuticals such as fluorine-18 and astatine-211 for positron emission tomography (PET) imaging and targeted alpha-radionuclide therapy. TetraKit's innovative approach incorporates proprietary click chemistry and a modular design, which allows for rapid and mild labeling conditions across a variety of molecules. This platform enhances the efficiency of production processes in the field of radiopharmaceuticals, enabling medical professionals to leverage advanced technologies in cancer treatment and imaging.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

JaxBio develops AI-driven diagnostic technology for cancer, using AI-based chips for genetic and epigenetic profiling and array-based cancer tests to enable a simple, sensitive blood test for cancer detection and monitoring. Its technology identifies biomarker sets that distinguish cancer types and subtypes across stages, supporting early detection, disease monitoring, and prediction of treatment response.

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Vaxdyn is a biotechnology company focused on the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. Utilizing innovative technology, Vaxdyn's vaccines incorporate antigens, immunomodulators, nanoparticles, and monoclonal antibodies to effectively combat bacterial infections. This approach helps healthcare professionals mitigate the public health impact of infections that are resistant to traditional treatments. The company actively engages with its customers through various communication channels, including phone, email, and online applications, to address inquiries related to their vaccine offerings.

Vaxdyn is a biotechnology company focused on the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. Utilizing innovative technology, Vaxdyn's vaccines incorporate antigens, immunomodulators, nanoparticles, and monoclonal antibodies to effectively combat bacterial infections. This approach helps healthcare professionals mitigate the public health impact of infections that are resistant to traditional treatments. The company actively engages with its customers through various communication channels, including phone, email, and online applications, to address inquiries related to their vaccine offerings.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

Scope Biosciences develops molecular diagnostics leveraging CRISPR-Cas technology. It originated as a spin-off from Wageningen University & Research. The company aims to provide actionable nucleic acid detection in healthcare and agriculture with high specificity for single-nucleotide differences and sensitivity to trace genetic material, packaged in a format that can be used outside traditional laboratory settings to support on-site decision making by clinicians and agricultural professionals.

AptaTargets is a biopharmaceutical company developing therapeutic applications based on aptamer technology. The company advances drug candidates from preclinical stages toward clinical development with the aim of reaching phase 2 trials. Its approach uses aptamers to recognize specific therapeutic targets, offering an antibody-like mechanism with potential advantages in precision and safety. The pipeline addresses inflammatory and neuroprotective indications, including conditions such as ischemic stroke, myocardial infarction, and autoimmune diseases, and seeks to modulate disease pathways through targeted molecular recognition.

O11 Biomedical GmbH is a spin-off from RWTH Aachen University's Institute for Applied Medical Engineering, specifically the Department of Biohybrids & Medical Textiles. The company specializes in liquid breathing technology aimed at treating hypercapnia, a condition characterized by elevated carbon dioxide levels in the blood. O11 Biomedical's innovative technology effectively binds carbon dioxide from intestinal fluid, facilitating its excretion through natural processes. By doing so, the company seeks to enhance both the survival and quality of life for patients afflicted with this respiratory condition.

BetaGlue Technologies SpA is a Milan-based company that specializes in the development and manufacture of medical devices designed for loco-regional radiation therapy targeting unresectable solid tumors. The company's innovative product features a proprietary beta-emitting biocompatible matrix, which facilitates the controlled administration of radionuclides directly into tumor masses. This technology not only enhances the effectiveness of cancer treatment but also plays a crucial role in preventing complications that can arise following procedures such as lung and liver biopsies. By focusing on localized therapies, BetaGlue Technologies aims to improve patient outcomes and advance the field of cancer treatment.

Founded in 2017, Nectin Therapeutics develops novel monoclonal antibodies targeting the Nectin family of receptors and ligands. These antibodies aim to treat solid and hematological malignancies by modulating immune checkpoint mechanisms.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective and safe options for managing chronic pain and hearing loss. Through its research and development efforts, Hoba Therapeutics seeks to deliver disease-modifying treatments that enhance the quality of life for patients suffering from neuropathic pain.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

Genewity B.V. is a biotech company that works closely with LUmc to build on the achievements of our scientific and business teams in cell and gene therapies.

PannTheraPi is a biotechnology company focused on developing therapies for brain and nervous system diseases. It operates a discovery program grounded in human tissue studies and seeks to identify novel targets and develop Pannexin channel blocker drugs. By pursuing repurposed, safety-validated compounds, it aims to expand treatment options and accelerate access to medicines addressing unmet neurological needs.

Celtic Biotech is a biotechnology company focused on developing innovative therapies for the treatment of solid cancers and pain in humans. Co-founded by John Reid, the company utilizes specialized receptor-binding proteins derived from snake venom to create its therapeutic products. These novel candidate therapies aim to enhance patient survival rates, improve quality of life, and reduce the overall costs of cancer treatment. By leveraging unique biological mechanisms, Celtic Biotech addresses significant medical challenges in oncology and pain management.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

Better Medicine develops an AI-powered radiology platform aimed at streamlining cancer diagnostics. Its platform offers multi-organ analysis, automated lesion detection, integrated reporting tools, and compatibility with existing systems, enabling healthcare providers to enhance diagnostic accuracy and deliver personalized care.

Angiolutions develops innovative therapeutic devices focused on treating vascular diseases, notably minor abdominal aortic aneurysms. Their groundbreaking approach involves a novel vascular graft designed to halt the growth of these aneurysms.

BioSimulytics is a company that specializes in creating AI-powered software tailored for drug researchers in the pharmaceutical industry. Its innovative platform integrates molecular chemistry, quantum physics, and advanced artificial intelligence to enhance the drug development process. By focusing on crystal-structure prediction, BioSimulytics enables researchers to accurately predict stable polymorphs, which significantly improves the speed, certainty, and quality of product data. This technology aims to streamline the development of pharmaceuticals, ultimately supporting researchers in their quest to bring new drugs to market more efficiently.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Xenothera is a biotechnology company that specializes in xenotherapy, focusing on the development of innovative immunological treatments. Utilizing a unique technological platform, Xenothera combines expertise in animal genetics with advanced immunology processes to create new therapeutic approaches for various medical conditions, including immunomodulation and infectious diseases. The company is particularly noted for its development of hyperimmune polyclonal sera, which represents a new generation of passive immunotherapy. By controlling the entire process—from the selection of immunogens to the purification of immunoglobulins—Xenothera is able to accelerate the development and market authorization of its therapies, thereby facilitating timely access to novel treatments for patients.

Strolll is a digital health company focused on improving mobility for people with neurological disorders. It develops a B2B digital therapeutics platform that delivers clinically validated rehabilitation software on off-the-shelf augmented reality glasses. The platform supports both in-clinic (synchronous) and at-home (asynchronous) therapy, enabling rehabilitation clinics to scale services, improve access, and reduce the cost of neurorehabilitation. By personalizing therapy, the solution aims to increase patient adherence and outcomes while streamlining administrative processes and delivering meaningful data to clinics.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

Nimble Diagnostics is a company that offers a range of DNA testing services, including paternity testing, prenatal gender testing, family relationship testing, ancestry DNA testing, and DNA art. In addition to these services, the company provides cancer nutraceuticals, aiming to support patients' health and well-being. Nimble Diagnostics leverages the internet to deliver its offerings globally at affordable prices, maintaining a commitment to accessible molecular diagnostics. The company also focuses on developing medical monitoring devices that enhance patient care, particularly for individuals with medical implants. These devices enable continuous, non-invasive monitoring, allowing healthcare providers to transition from reactive to proactive care, thereby reducing clinical complications associated with implanted stents.

ReST Therapeutics is a clinical biotechnology company focused on developing innovative therapies for complex central nervous system (CNS) disorders. Utilizing its patented medication candidate, the company aims to create treatments that selectively target NMDA receptors, with the intention of addressing conditions such as post-traumatic stress disorder (PTSD) and Alzheimer's disease. By advancing its candidate through non-clinical testing, ReST Therapeutics seeks to improve the efficacy of cognitive preservation and provide protection against neurotoxicity, thereby enhancing therapeutic outcomes for patients suffering from these debilitating neural disorders.

MaxiVAX is a Swiss clinical-stage biotechnology company developing personalized cancer immunotherapies. Its lead product, MVX-ONCO-1, is an advanced therapeutic product for various tumors, currently in phase I trials.